Medicenna Picked to Deliver Oral Presentation on Bizaxofusp at Neuro-Oncology Meeting in November

11:51 AM EDT, 09/24/2026 (MT Newswires) -- Medicenna Therapeutics (MDNA.TO) said Thursday that it has been selected to deliver an oral presentation on its immunotherapy candidate bizaxofusp (formerly MDNA55) at a Society for Neuro-Oncology (SNO) meeting in Philadelphia in November. The presentation, to be delivered by Nicholas Butowski, professor of Neurological Surgery at the University of California, San Francisco, will evaluate survival outcomes in patients with a certain type of recurrent glioblastoma (rGBM), a statement said. "Selection for an oral presentation at SNO highlights the interest of the neuro-oncology community in the continued clinical development of bizaxofusp for patients with recurrent glioblastoma," said Fahar Merchant, Medicenna's chief executive officer. "We look forward to presenting this survival analysis in the intended Phase 3 population and continue engaging with leading clinicians, researchers and potential pharma partners during SNO 2026." Medicenna shares were last seen up CA$0.005 at CA$0.41 on the Toronto Stock Exchange.